Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…


Got arthritis? DNAlytics has an app for it!

Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis - a chronic, inflammatory disease causing deformity of …

POPULAR TAGS

Good news after good news for Biocartis

Written by LVS on in the category news with the tags .


After the Idylla test for lung cancer was recognized as best-in-class in a recent study, Biocartis also receives a € 2.5 million grant from the Flemish government.

In a study comparing lung-cancer detection assays, Biocartis’ test came out as best-in-class. The study, carried out by pharma giant AstraZeneca, compared 12 technologies detecting the KRAS-mutation, the most common driver of non-small-cell lung cancer (NSCLC). The Idylla™ KRAS test belonged to the group of most sensitive tests but completely wiped out the competition in terms of ease-of-use and time-to-result. While the Biocartis test provided results in 2 to 4 hours, alternative methods took 1 day to 3 weeks to complete. The recently published study confirms the status of Idylla™ tests as sensitive, easy to use and lightning fast.

“We are extremely proud with the results of this study organized by a leading global pharmaceutical company like AstraZeneca,” responds CEO Rudi Pauwels. “This is the broadest comparison study conducted by an external party on Idylla™ performance to date with respect to the number of different technologies applied on one sample set. It demonstrates that with the Idylla™ technology, we can truly combine the advantages of point-of-care testing in terms of ease-of-use and speed with the performance that one would expect from technologies used in reference laboratories. As such, the Idylla™ technology has the potential to make rapid molecular diagnostic testing available in any routine diagnostic lab setting - large or small."

Investors responded enthusiastically to the news and propelled the company’s stock price 20% higher.

And that wasn’t even all of the good news. The Flemish government announced that it would support Biocartis with a € 2.5 million grant. Biocartis will use the funds for the expansion of their manufacturing capacity. At the moment, Biocartis produces 200.000 to 250.000 Idylla™ tests each year. The new production line, expected to be operational in 2017, will crank up production to 1 million tests produced annually. The investment will also create about 100 jobs in the coming 5 years.

More news on Biocartis here

Read more about: .

RELATED ARTICLES
Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…


Got arthritis? DNAlytics has an app for it!

Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis - a chronic, inflammatory disease causing deformity of …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation Itera Life Science Biowin V-Bio Ventures UGent KU Leuven Flanders.bio Janssen Turnstone GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.